Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Official Title

A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy


To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumour activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.

Trial Description

Primary Outcome:

  • Incidence of dose limiting toxicities (DLTs)
  • Safety and tolerability of LSZ102, LSZ102 + LEE011 and LSZ102 + BYL719
Secondary Outcome:
  • Overall response rate (ORR)
  • Duration of Response (DOR)
  • Progression Free Survival (PFS)
  • Disease control rate (DCR)
  • Plasma concentration of study medications
  • Plasma concentration under fasted condition and fed condition
  • Levels of Pharmacodynamic marker Estrogen receptor (ER)
  • Levels of Pharmacodynamic marker Progesterone receptor (PgR)
  • Levels of Pharmacodynamic marker pS6
  • Pharmacokinetics (PK) parameter AUC
  • PK parameter Cmax
  • PK parameter Tmax
  • PK parameter Cmin

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society